Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study

Hepatology Research

Volumn 44, Issue 5, 2014, Pages 523-531

  Wang, Shen Nien ^a,b   Chuang, Shih Cheng ^a,b   Lee, King Teh ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adjuvant therapy; Hepatocellular carcinoma; Liver resection; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK;

EID: 84899048814     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12159     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mather SC, Parkin DM. Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. EI-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
4. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-1547.
6. Chun JM, Kwon HJ, Sohn J etal. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol 2011; 103: 148-151.
7. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
8. Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16: 413-422.
9. Lim KC, Chow PK, Allen JC etal. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: 108-113.
10. Lee KT, Lu YW, Wang SN etal. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99: 343-350.
11. Fan ST, Poon RT, Yeung C etal. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg 2011; 98: 1292-1300.
12. Eguchi S, Kanematsu T, Arii S etal.; Liver Cancer Study Group of Japan. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 552-557.
13. Lee KT, Wang SN, Su RW etal. Is wider surgical margin justified for better clinical outcomes in patients with resectable hepatocellular carcinoma? J Formos Med Assoc 2012; 111: 160-170.
14. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
15. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
16. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
17. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011; 81 (Suppl 1): 50-55.
18. Andreana L, Burroughs AK. Treatment of early hepatocellular carcinoma: how to predict and prevent recurrence. Dig Liver Dis 2010; 42: S249-257.
19. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-37.
20. NCI. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006.
21. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 2012; 99: 1622-1629.
22. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207.
23. Portolani N, Coniglio A, Ghidoni S, Giovanelli M. Early and late recurrence after liver resection for hepatocellular carcinoma- prognostic and therapeutic lmplications. Ann Surg 2006; 243: 229-235.
24. Plessier A, Codes L, Consigny Y, Sommacale D. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10: S86-90.
25. Wu JC, Huang TH, Chau GY etal. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-897.
26. Chen Y, Yeh SH, Chen JT etal. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000; 119: 431-440.
27. Finkelstein SD, Marsh W, Demetris AJ etal. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003; 37: 87-89.
28. Ng I, Guan X, Poon R, Fan ST, Lee JM. Determination of nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003; 199: 345-353.
29. Zhon XD, Tang ZY, Yang BH etal. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91: 1479-1486.
30. Vauthey J, Lauwers G, Esnaola N etal. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20: 1527-1536.
31. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function : implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-382.
32. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214: 114-117.
33. Kumada T, Nakano S, Takeda I etal. Patterns of recurrence after intial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
34. Ercolani G, Grazi GL, Ravaioli M etal. Liver resection for hepatocellular carcinoma on cirrhosis. Ann Surg 2003; 237: 536-543.
35. Wong JS, Wong GL, Tsoi KK etal. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33: 1104-1112.
36. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287-292.
37. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma: a meta-regression approach. J Hepatol 2010; 52: 889-894.
38. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK. Preoperative transcatheter arterial chemoembolization for respectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122-126.
39. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma. Arch Surg 1998; 133: 183-188.
40. Poon RT, Fan ST, Wong J. Risk factor, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
41. Prints C. Clinical trials of note. Sorafenib as adjuvant treatment for the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009; 115: 4646.
42. Wang Z, Hu J, Qiu SJ etal. An investigation of the effect of sorafenib on tumor growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Expert Opin Investig Drugs 2011; 20: 1039-1045.
43. Feng YX, Wang T, Deng YX etal. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotropic mouse model. Hepatology 2011; 53: 483-493.
44. Kaneko S, Furuse J, Kudo M etal. Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. Hepatol Res 2012; 42: 523-542.